Greater Accuracy With Less Ambiguity
Artificial Intelligence Meets Biology
Leveraging artificial intelligence-based technology, DecisionDx® DiffDx™-Melanoma is an objective test with a high level of accuracy, low technical failure, low intermediate risk, and an inclusion of a variety of both benign nevi and malignant lesions.
Neural networks are used to identify 32 genes spanning a range of important biological processes, along with 3 control genes, to best classify melanocytic lesions.
Two proprietary algorithms are applied to the gene expression patterns to identify the malignant potential of a lesion.
One clinically actionable result in over 96% of the cases including multiple types of benign nevi and malignant melanoma.
DiffDx-Melanoma Genes By Function
*Genes also included in DecisionDx®-Melanoma assay.